This Wednesday, May 26, the European Medicines Agency (EMA) said that a conference would be held on Friday, May 28. During this meeting, the experts will decide: they will validate or not the use of the Pfizer / BioNtech vaccine in young people aged between 12 and 15 years.
What scenario is envisaged?
It is therefore this Friday that the Pfizer vaccine will be approved or not for pre-adolescents 12 to 15 years old, according to the EMA. In the event that it is authorized for this age group, the American serum will be the first to obtain an agreement from the European regulator. It can then be administered to young people in the 27 member countries of the European Union. For now, it is from the age of 16 that the Pfizer vaccine can be used. To make its decision, the EMA will hold a press conference to share the ” results of an extraordinary meeting of its Committee for Medicinal Products for Human Use (…) concerning the pediatric indications of the Comirnaty vaccine “. As a reminder, Comirnaty is the trade name given to the vaccine developed by the American laboratory Pfizer and the German pharmaceutical company BioNtech.
Already authorized in the United States
The US Medicines Agency has already given the green light to use the Pfizer vaccine in 12-15 year olds.
In addition, Emer Cooke, the director of the EMA, said in early May that an accelerated assessment of data submitted by vaccine manufacturers would be carried out. Originally, the results were expected in June.
